Aeglea BioTherapeutics, Inc.(AGLE) - 2025 Q1 - Quarterly Results

Announced first participant dosed in Phase 1 trial of SPY003, with interim PK and safety data readout on track for the second half of 2025 Exhibit 99.1 Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027 Reported extended follow-up Phase 1 data for SPY001, supporting that the molecule is ...